Alpa Laboratories Share Price Today | Stock Price & Alpa Laboratories Share Screener
As of October 5, 2026, the live Alpa Laboratories share price (NSE: ALPA) is ₹59.00 on NSE and ₹59.09 on BSE, down 0.44% from the previous close, with shares trading between ₹58.25 and ₹60.25 in today's trading session, and a 52-week range of ₹46.46–₹92.01. Check ALPA yearly price range for the annual price range and momentum. Use the Alpa Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Alpa Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹31 and net income of ₹1, with EBITDA of ₹3, an operating margin of 11.0% and a profit margin of 3.2%.
Alpa Laboratories Share Price Chart
Track the current stock price of Alpa Laboratories with an interactive chart. Analyse ALPA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Alpa Laboratories stock quote in one place.
The quote of ₹59.00 sits between the 52-week low of ₹46.46 and the 52-week high of ₹92.01, and the latest session moved -0.44% from the previous close.
Alpa Laboratories Company Profile - Fundamental Screener
Screen Alpa Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ALPA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE385I01010.
Company Details
Classification
Identifiers and Leadership
Alpa Laboratories Balance Sheet Screener
Screen ALPA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹242, up from ₹223 in 2025.
Latest statistics put total assets at ₹242 and shareholder funds at ₹186, with a leverage ratio of 0.01.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 242 | 223 | 182 | 167 | 155 | 140 | 121 | 121 | 122 | 126 |
| Current Assets | 211 | 193 | 161 | 149 | 138 | 121 | 96 | 94 | 98 | 105 |
| Fixed Assets | 20 | 21 | 12 | 7 | 9 | 7 | 6 | 8 | 10 | 15 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3 | 5 | 2 | 3 | 2 | 0 | 0 | 0 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 186 | 171 | 152 | 135 | 122 | 108 | 100 | 99 | 98 | 95 |
| Share Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves & Surplus | 165 | 150 | 131 | 114 | 101 | 87 | 79 | 78 | 77 | 74 |
Alpa Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Alpa Laboratories income statement and profit fundamentals. Analyze ALPA quarterly results. Alpa Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹31 and net profit was ₹1, equal to earnings per unit of ₹0.24, at an operating margin of 11%.
In that period expenses were ₹28, interest cost ₹0 and tax ₹2. The next period listed, 2026-Jun, shows revenue of ₹30 and net profit of ₹1.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 31 | 30 | 42 | 31 | 29 | 30 | 28 | 27 | 27 | 32 | 35 | 29 | 30 | 35 | 31 |
| Expenses | 28 | 28 | 40 | 19 | 29 | 28 | 20 | 21 | 21 | 22 | 25 | 20 | 27 | 29 | 25 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 3 | 2 | 3 | 12 | 1 | 2 | 8 | 6 | 6 | 10 | 10 | 9 | 3 | 6 | 6 |
| Operating Profit % | 11.00% | -17.00% | 1.00% | 2.00% | -9.00% | 5.00% | 15.00% | 2.00% | 2.00% | 13.00% | 3.00% | 32.00% | -4.00% | 10.00% | 9.00% |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 3 | 1 | 2 | 12 | 0 | 2 | 7 | 5 | 5 | 10 | 9 | 8 | 3 | 6 | 5 |
| Tax | 2 | 0 | 4 | 0 | 0 | 0 | 3 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 1 |
| Net Profit | 1 | 1 | -2 | 12 | 0 | 2 | 4 | 5 | 5 | 8 | 9 | 5 | 3 | 6 | 5 |
| EPS | 0.24 | 0.49 | -0.95 | 5.59 | 0.05 | 0.76 | 1.71 | 2.42 | 2.42 | 3.66 | 4.23 | 2.12 | 1.44 | 2.75 | 2.17 |
Alpa Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen ALPA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹9, and net cash flow was an inflow of ₹1.
Over the same period, investing activities used ₹11 and financing activities provided ₹2.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 9 | 18 | 4 | 9 | 10 | -2 | 18 | -1 | -13 | 17 |
| Investing Activities | -11 | -12 | -13 | 2 | -16 | 6 | -11 | -15 | -12 | -2 |
Financing and Net Cash | ||||||||||
| Financing Activities | 2 | -5 | 3 | -4 | 5 | 0 | -1 | -5 | 9 | -15 |
| Net Cash Flow | 1 | 1 | -7 | 7 | 0 | 4 | 5 | -20 | -15 | 0 |
Alpa Laboratories Shareholding Pattern Screener
See Alpa Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Alpa Laboratories promoter holding and ownership changes for ALPA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 57.19%, foreign institutions 0.38%, domestic institutions 0.00% and the public 36.75%, spread across 17,900 shareholders.
The shareholder count was 17,900 in 2026-Mar, compared with 17,643 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 57.19% | 57.19% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% |
Institutional Investors | ||||||||
| FII Holding | 0.38% | 0.35% | 0.40% | 0.36% | 0.35% | 0.36% | 0.50% | 0.36% |
| DII Holding | 0.00% | 0.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 36.75% | 36.66% | 37.32% | 37.28% | 37.14% | 36.78% | 36.83% | 36.65% |
| Other Holding | 5.68% | 5.73% | 4.99% | 5.06% | 5.21% | 5.57% | 5.37% | 5.70% |
| Shareholder Count | 17,900 | 17,643 | 18,872 | 18,851 | 18,542 | 18,236 | 18,690 | 18,116 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Alpa Laboratories. Alpa Laboratories dividend yield can be compared with peers and other stocks in the market.
Alpa Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Alpa Laboratories stock. Check ALPA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Alpa Laboratories Market Events Screener - Corporate Actions
Get Alpa Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Alpa Laboratories stock events that may affect ALPA share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Quarterly Result Announcement dated August 13, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -4.79% |
| 2026-08-13 | 2026-08-13 | Quarterly Result Announcement | NA | 0.54% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 1.19% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 17.61% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -5.54% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | -4.36% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -5.48% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 4.02% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.57% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -1.67% |
| 2024-09-28 | 2024-09-28 | Annual General Meeting | NA | 10.89% |
| 2023-09-29 | 2023-09-29 | Annual General Meeting | NA | -9.25% |
Alpa Laboratories Competitors Screener - Peer Stocks Comparison
Screen ALPA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,010 | 35.84 | 61,674 | 12.69% | 11,565 | 33.78 |
| Divis Laboratories | 244,125 | 84.36 | 11,067 | 13.95% | 2,568 | 49.73 |
| Torrent Pharmaceuticals | 181,512 | 84.01 | 13,886 | 20.34% | 2,138 | 41.48 |
| Zydus Life Science | 113,616 | 24.88 | 27,658 | 17.64% | 5,026 | 46.18 |
| Cipla | 107,890 | 32.42 | 29,045 | 2.24% | 3,870 | 32.87 |
| Laurus Labs | 106,517 | 98.56 | 6,868 | 22.01% | 890 | 56.11 |
| Mankind Pharma | 102,394 | 50.48 | 14,636 | 14.85% | 1,938 | 55.53 |
| Dr Reddys Laboratories | 100,412 | 31.47 | 35,059 | 3.90% | 4,158 | 52.91 |
| Aurobindo Pharma | 96,370 | 25.97 | 34,145 | 5.56% | 3,503 | 49.89 |
| Lupin | 91,961 | 16.71 | 29,039 | 26.75% | 5,356 | 29.12 |
Alpa Laboratories Company Announcements - News & Reports Screener
Screen ALPA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated September 30, 2026 and September 17, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-30 | Closure of Trading Window | - |
| 2026-09-17 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-09-07 | Reg. 34 (1) Annual Report. | - |
| 2026-09-07 | Fixes Book Closure For The Purpose Of AGM. | - |
| 2026-09-07 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-13 | Results For The Quarter Ended June 2026 | - |
| 2026-08-11 | CLARIFICATION ON BOARD MEETING | - |
| 2026-08-04 | Board Meeting Intimation for Approval Of The Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30Th June 2026 | - |
| 2026-07-29 | Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Materiality Of Information | - |
| 2026-07-22 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-07-08 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-06-25 | Closure of Trading Window | - |
| 2026-05-29 | Results For The Quarter And Year Ended March2026 | - |
| 2026-05-12 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-04-11 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-04-09 | Clarification | - |
| 2026-04-08 | Clarification Sought from Alpa Laboratories Ltd | - |
| 2026-03-20 | Closure of Trading Window | - |
| 2026-03-09 | Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹59.00, within a 52-week range of ₹46.46 to ₹92.01. The P/E ratio is 31.08 and the P/B ratio is 0.68, with earnings per unit of ₹0.24. Market capitalisation stands at ₹124.14 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.